BioLineRx Ltd. (NASDAQ:BLRX – Free Report) shares are scheduled to reverse split on Thursday, January 30th. The 1-40 reverse split was announced on Friday, January 17th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 29th.
BioLineRx Stock Performance
Shares of BioLineRx stock opened at $0.10 on Friday. The firm has a market cap of $8.11 million, a PE ratio of -0.46 and a beta of 1.46. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. BioLineRx has a 52 week low of $0.08 and a 52 week high of $1.44. The business’s fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.49.
Analyst Upgrades and Downgrades
A number of research analysts have commented on BLRX shares. StockNews.com initiated coverage on shares of BioLineRx in a research report on Saturday, January 11th. They issued a “hold” rating on the stock. HC Wainwright decreased their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of BLRX. CVI Holdings LLC purchased a new stake in shares of BioLineRx in the 2nd quarter valued at $462,000. PVG Asset Management Corp acquired a new position in BioLineRx in the 2nd quarter valued at about $70,000. Finally, Atria Investments Inc increased its stake in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the period. 1.56% of the stock is currently owned by hedge funds and other institutional investors.
BioLineRx Company Profile
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Recommended Stories
- Five stocks we like better than BioLineRx
- Most Volatile Stocks, What Investors Need to Know
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Golden Cross Stocks: Pattern, Examples and Charts
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.